{"id":"F2009L01699","name":"Therapeutic Goods Act 1989 - Order under subsection 3(1) - Definition of British Pharmacopoeia (04/05/2009)","slug":"therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":78561,"registerId":"commonwealth-F2009L01699-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Therapeutic Goods Act 1989 - Order under subsection 3(1) - Definition of British Pharmacopoeia (04/05/2009)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![](image.001.png)\n\n \n\n \n\nTHERAPEUTIC GOODS ACT 1989\n\n \n\nORDER UNDER SUBSECTION 3(1) – DEFINITION OF BRITISH PHARMACOPOEIA\n\n \n\nI, CHARLES MASKELL-KNIGHT, delegate of the Minister for Health and Ageing for the purposes of the exercise of the Minister’s power under the definition of “British Pharmacopoeia” in subsection 3(1) of the Therapeutic Goods Act 1989 (“the Act”) and acting under that provision, HEREBY SPECIFY that on and from 1 June 2009 the definition of “British Pharmacopoeia” in the Act shall be the British Pharmacopoeia 2009.\n\n \n\n \n\nDated this      4th       day of May 2009\n\n \n\n \n\n \n\n \n\nSigned\n\n \n\nCHARLES MASKELL-KNIGHT\n\nA/g National Manager\n\nTherapeutic Goods Administration\n\n(Delegate of the Minister for Health and Ageing)\n\n \n","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":1789},"content_quality":"ok","complexity_score":1,"scope_assessment":{"changed":false,"description":"The instrument performs exactly the limited technical function authorised by subsection 3(1)—updating the statutory reference to the current edition of the British Pharmacopoeia. There is no expansion beyond the original purpose of the definitional power."},"complexity_factors":["Single operative provision updating one definition","No conditional logic, exceptions, or cross-references","Extremely short length (one page)","No interpretative provisions or defined terms"],"plain_english_summary":"This Order updates the definition of **British Pharmacopoeia** in the Therapeutic Goods Act 1989.\n\n**What it does:**\n- Specifies that when the Act refers to the \"British Pharmacopoeia\", it means the **British Pharmacopoeia 2009** (the official UK standards book for medicines)\n- The new definition takes effect on **1 June 2009**\n\n**Why it matters:**\nThe Therapeutic Goods Act uses the British Pharmacopoeia as a benchmark for the quality, purity, and strength of medicines in Australia. By updating the reference to the 2009 edition, the law ensures that Australian therapeutic goods must meet current international standards.\n\n**Who it affects:**\nThis primarily affects pharmaceutical companies and manufacturers who must ensure their products comply with the standards set out in the 2009 British Pharmacopoeia."}},"importantCases":[],"_links":{"self":"/api/acts/therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009","history":"/api/acts/therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009/history","analysis":"/api/acts/therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009/analysis","conflicts":"/api/acts/therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009/conflicts","importantCases":"/api/acts/therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009/important-cases","documents":"/api/acts/therapeutic-goods-act-1989-order-under-subsection-3-1-definition-of-british-pharmacopoeia-04-05-2009/documents"}}